

Turning the page: a welcome from the new leadership of the Journal of Infectious Diseases

Cynthia L. Sears, MD¹ Jonathan Z. Li, MD, MMSc² and Upinder Singh, MD³

¹School of Medicine, Johns Hopkins University, Baltimore, MD, USA; ²Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; and ³Stanford Medicine, Stanford, CA, USA

TO OUR AUTHORS AND READERS—This 1 January 2023 issue marks the transition of the editorial board for *The Journal of Infectious Diseases* (JID), the flagship journal (founded in 1904) of the Infectious Diseases Society of America (IDSA). For the past 20 years, JID has been expertly led through the numerous discoveries, scientific advances, and emerging pathogens by its Editor-in-Chief, Dr Martin S. Hirsch, an internationally renowned virologist, researcher, and scholar [1]. More simply put, Marty is both wise and humble, bringing his thoughtfulness, scientific insight, communication skills, and delightful sense of humor to this position. He has been skillfully assisted by Dr David C. Hooper as his Deputy Editor and 12 talented Associate Editors whose judgment and editorial skills enabled JID to flourish (Table 1). As the incoming leaders of JID, we have been so fortunate to benefit from the experience and guidance of Dr Hirsch and the current JID scientific board.

Of course, change can bring both uncertainty and opportunity. So, what can our authors and readers expect? The bedrock of JID, now and going forward, is to promote and publish outstanding

infectious diseases science, spanning bench, clinical, translational, and cross-disciplinary research. Amongst the articles published in JID, the virology and malaria science research, in particular, have been standouts, with seminal articles that have shaped the direction of these fields. We hope to further expand JID's leadership in other areas of the infectious diseases field, for example, in translational microbiome science, clinical field trials, or clinical science with strong, supportive bench science, among others. Additionally, we hope to rapidly inform our readership through presentation of short articles, designed for rapid reader review, on current or topical areas within the infectious diseases field in a new, nimble format called "Viewpoint." The first Viewpoint will be online in early 2023 and all Viewpoints will be available on the JID website. However, we expect other headers to emerge as we weave in insights on mentorship, career development, scientific implications of clinical trials, statistical testing, reflections on infectious diseases history, and progress on inclusion, diversity, access, and equity (IDAE) [2, 3], among others. Furthermore, we are developing a "Clinician's Corner" where astute observations at the bedside or bench enhance our disease insights. For example, the first HIV cure in a bone marrow transplant patient was confirmation of the importance of the discovery that a 32-bp deletion in the *CCR5* allele provides resistance against HIV-1 acquisition [4–7].

From a practical perspective, the basic approach to evaluating the science of JID manuscripts will remain largely intact.

However, we want to ease the burden of manuscript submission by instituting format-free initial submissions, except for inclusion of line and page numbers that assist the rapid, accurate review of manuscripts. Using this approach, authors will apply full JID formatting standards at the time of manuscript revisions. We plan to test new approaches such as using graphical (visual) abstract tools and author podcasts to assist our authors in developing readily digestible displays of their work. These tools, in turn, will help with distribution of the work of our authors by newly expanded social media support within IDSA's publications team. The appearance of JID will improve by providing Advanced Access articles in a standard journal pdf presentation that we consider more accessible for review by our readers. We, along with *Clinical Infectious Diseases* and *Open Forum Infectious Diseases*, are committed to expanding and enhancing cross-talk amongst IDSA's journals.

In this issue, you can peruse our biographies and familiarize yourself with the expertise we each bring to JID. In each of the next 4 issues of JID, 4 of our Associate Editors as well as our Statistical Editors will be similarly highlighted. In our quest to bring superb Associate Editors to JID, we drew extensively on the diversity within our infectious diseases community. We are 47% women, 40% individuals of color, range in age from under 40 to over 60 years, and represent all US geographical regions and Europe (Spain). In addition to our hope that our biographies enable you to

Received 29 September 2022; editorial decision 29 September 2022; accepted 29 September 2022

Correspondence: C. L. Sears, MD, Division of Infectious Diseases, Johns Hopkins University School of Medicine, 1550 Orleans Street, Baltimore, MD 21231 (csears@jhmi.edu).

The Journal of Infectious Diseases® 2023;227:1–3

© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com

<https://doi.org/10.1093/infdis/jiac400>

Table 1. Journal of Infectious Diseases Departing Editors

Name	Editorial Role	Years of Service
Martin S. Hirsch, MD	Editor-in-Chief	2003–2022
David C. Hooper, MD	Deputy Editor	2003–2022
Marcel Behr, MD	Associate Editor	2013–2022
Raymund Chung, MD	Associate Editor	2003–2022
Peter Densen, MD	Associate Editor	2004–2022
Joseph A. Kovacs, MD	Associate Editor	2003–2022
Daniel R. Kuritzkes, MD	Associate Editor	2003–2022
Stuart M. Levitz, MD	Associate Editor	2013–2022
William Schaffner, MD	Associate Editor	2003–2022
Jane R. Schwebke, MD	Associate Editor	2003–2022
Frederick S. Southwick, MD	Associate Editor	2003–2022
Peter F. Weller, MD, MACP	Associate Editor	2003–2022
Richard J. Whitley, MD	Associate Editor	2004–2022

understand better the broad range of infectious diseases science we represent, we expect that our diversity will be a springboard for novel ideas and energetic leadership reflected in the pages of JID.

Thank you for continuing to consider JID as a prime place to publish your clinical, translational, and laboratory-based infectious disease research and for your support during this transition. We look forward to your feedback in this new journey for JID.

Introducing the New Journal of Infectious Diseases Editors

The *Journal of Infectious Diseases* is pleased to introduce our new Editor-in-Chief, Cynthia L. Sears, and Deputy Editors Upinder Singh and Jonathan Z. Li.

Editor-in-Chief



Cynthia L. Sears, MD, is Professor of Medicine, Oncology, and Molecular

Microbiology and Immunology at the Johns Hopkins University School of Medicine and the Bloomberg School of Public Health and the Microbiome Program Leader of the Bloomberg~Kimmel Institute for Cancer Immunotherapy. Clinically, she focuses on gut infections. She enjoys conducting human translational and bench research stemming from her training as an infectious diseases specialist. Her laboratory focuses on how enteric bacteria and the microbiome promote colon carcinogenesis and modulate cancer immunotherapy responses. She has long been an active member of the Infectious Diseases Society of America, serving as President of IDSA in 2019.

Deputy Editors



Jonathan Z. Li, MD, is an Associate Professor of Medicine in the Division of Infectious Diseases at the Brigham and Women's Hospital and Harvard Medical School. He is the Director of

the Harvard/Brigham Virology Specialty Laboratory and the Director of the Harvard University Center for AIDS Research Clinical Core. Dr. Li is the chair of two clinical studies in the AIDS Clinical Trials Group and serves on the ACTG Executive Committee. He is also a member of the NIH COVID-19 Therapeutics Guidelines Panel. His research focus is in viral persistence, reservoirs, and drug resistance.



Upinder Singh, MD, is Professor of Medicine, Infectious Diseases, and Microbiology and Immunology at Stanford University School of Medicine. She serves as the Division Chief for Infectious Diseases and the Associate Chair for Faculty Development for the Department of Medicine. Her research program focuses on basic and translational studies of parasitic agents with an emphasis on amebic pathogens. More recently she has been working on COVID-19 treatment strategies and studies of long COVID. She has been an active member of the Infectious Diseases Society of America and has served on the IDSA Research and Publications committees.

References

1. Hirsch MS. Farewell to *JID*. *J Infect Dis* **2022**; 226:2045–6.
2. Sears CL, del Rio C, Malani P. Inclusion, diversity, access and equity: enhancing the future of infectious diseases. *J Infect Dis* **2019**; 220: S27–9.
3. Li JZ, Sears CL, Chatterjee A. Inclusion, diversity, access and equity in infectious

- diseases: nurturing the next generation of clinicians, scientists and leaders. *J Infect Dis* **2020**; 222:S521–2.
4. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. *Cell* **1996**; 86:367–77.
 5. Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. *Nature* **1996**; 382:722–5.
 6. Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. *Science* **1996**; 273:1856–62. Erratum in: *Science* 1996; 274:1069.
 7. Hütter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. *N Engl J Med* **2009**; 360:692–8.